CASP-9: A susceptibility locus for multiple sclerosis in Italy

Journal of Neuroimmunology

Volumn 210, Issue 1-2, 2009, Pages 100-103

  Andreoli, V ^a   Trecroci, F ^a   La Russa, A ^a   Valentino, P ^b   Condino, F ^a   Latorre, V ^a   Nistico R ^b   Pirritano, D ^b   Del Giudice, F ^b   Canino, M ^b   Cittadella, R ^a   Quattrone, A ^a,b  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Association study; CASP 9; Genetic susceptibility; Multiple sclerosis; Polymorphism

Indexed keywords

ADULT; APOPTOSIS; ARTICLE; CASP 9 GENE; CELL DEATH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; APOPTOSIS; CASPASE 9; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67349260018     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.03.013     Document Type: Article

References (39)

1. Alcazar A., Regidor I., Masjuan J., Salinas M., and Álvarez-Cermeño J.C. Induction of apoptosis by cerebrospinal fluid from patients with primary-progressive multiple sclerosis in cultured neurons. Neurosci. Lett. 255 (1998) 75-78
2. Alcazar A., Regidor I., Masjuan J., Salinas M., and Álvarez-Cermeño J.C. Axonal damage induced by cerebrospinal fluid from patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 104 (2000) 58-67
3. Amirzargar A., Khosravi F., Dianat S., Hushmand F., Maryousef P., Foroushani A.R., Lotfi J., and Nikbin B. Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients. Mult. Scler. 13 2 (2007) 253-255
4. Bö L., Vedeler C.A., Nyland H., Trapp B.D., and Mörk S.J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9 (2003) 323-331
5. Cao G., Xiao M., Sun F., Xiao X., Pei W., Li J., Graham S.H., Simon R.P., and Chen J. Cloning of a novel Apaf-1-interacting protein: a potent suppressor of apoptosis and ischemic neuronal cell death. J. Neurosci. 24 (2004) 6189-6201
6. Cid C., Alcázar A., Regidor I., Masjuan J., Salinas M., and Alvarez-Cermeño J.C. Neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients correlates with hypointense lesions on T1 magnetic resonance imaging. J. Neurol. Sci. 193 (2002) 103-109
7. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
8. Costello F., Stuve O., Weber M.S., Zamvil S.S., and Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr. Opin. Neurol. 20 (2007) 281-285
9. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58 8 Suppl 4 (2002) S3-S9
10. Dhib-Jalbut S., Arnold D.L., Cleveland D.W., Fisher M., Friedlander R.M., Mouradian M.M., Przedborski S., Trapp B.D., Wyss-Coray T., and Yong V.W. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J. Neuroimmunol. 176 (2006) 198-215
11. Hadano S., Nasir J., Nichol K., Rasper D.M., Vaillancourt J.P., Sherer S.W., Beatty B.G., Ikeda J.E., Nicholson D.W., and Hayden M.R. Genomic organization of the human caspase-9 gene on chromosome 1p36.1-p36.3. Mamm. Genome. 10 7 (1999) 757-760
12. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufman S.A., Lowe S.W., Penninger J.M., and Mak T.W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 94 (1998) 339-352
13. Hirano A., Nagai H., Harada H., Haga S., Kajiwara T., and Emi1 M. Two novel single-nucleotide polymorphisms of the Caspase-9 (CASP9) gene in the Japanese population. Genes. Immun. 2 (2001) 117-118
14. Kantarci O.H., Hebrink D.D., Achenbach S.J., Atkinson E.J., de Andrade M., Mc Murray C.T., and Weinshenker B.G. CD95 polymorphisms are associated with susceptibility to MS in women. A population-based study of CD95 and CD95L in MS. J. Neuroimmunol. 146 (2004) 162-170
15. Kikuchi S., Miyagishi R., Fukazawa T., Yabe I., Miyazaki Y., and Sasaki H. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J. Neuroimmunol. 167 (2005) 170-174
16. Kuida K., Haydar T.F., Kuan C.Y., Gu Y., Taya C., Karasuyama H., Su M.S., Rakic P., and Flavell R.A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 94 (1998) 325-337
17. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
18. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
19. Liu J.R., Opipari A.W., Tan L., Jiang Y., Zhang Y., Tang H., and Núñez G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer. Res. 62 (2002) 924-931
20. Lublin F., and Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
21. Maier K., Merkler D., Gerber J., Taheri N., Kuhnert A.V., Williams S.K., Neusch C., Bähr M., and Diem R. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol. Dis. 25 (2007) 514-525
22. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
23. Meyer R., Weissert R., Diem R., Storch M.K., De Graaf K.L., Kramer B., and Bähr M. Acute neuronal apoptosis in a rat model of multiple sclerosis. J. Neurosci. 15 (2001) 6214-6220
24. Nicholson D.W., and Thornberry N.A. Caspases: killer proteases. Trends. Biochem. Sci. 22 (1997) 299-306
25. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 28 (2000) 938-952
26. Oksenberg J.R., Baranzini S.E., Barcellos L.F., and Hauser S.L. Multiple sclerosis: genomic rewards. J. Neuroimmunol. 113 (2001) 171-184
27. Peterson J.W., Bö L., Mörk S., Chang A., and Trapp B.D. Transected neurites, apoptotic neurons, and reduced in inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
28. Poser C., Paty D.W., and Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocol. Ann. Neurol. 33 (1983) 1444-1452
29. Sang T.K., Li C., Liu W., Rodriguez A., Abrams J.M., Zipursky S.L., and Jackson G.R. Inactivation of Drosophila Apaf-1-related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum. Mol. Genet. 14 (2005) 357-372
30. Shivapurkar N., Reddy J., Chaudhary P.M., and Gazdar A.F. Apoptosis and lung cancer: a review. J. Cell. Biochem. 88 5 (2003) 885-898
31. Srinivasula S.M. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell. 1 7 (1998) 949-957
32. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 3 (1996) 299-302
33. Stewart G.J. Multiple sclerosis, multiple genes. Med. J. Aus. 166 (1997) 573-574
34. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., and Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
35. Wolf B.B., Schuler M., Li W., Eggers-Sedlet B., Lee W., Tailor P., Fitzgerald P., Mills G.B., and Green D.R. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J. Biol. Chem. 276 (2001) 34244-34251
36. Yin Q., Park H.H., Chung J.Y., Lin S.C., Lo Y.C., da Graca L.S., Jiang X., and Wu H. Caspase-9 holoenzyme is a specific and optimal pro-caspasegenetic 3 processing machine. Mol. Cell 22 2 (2006) 25-268
37. Yong V.W. Prospects for neuroprotection in multiple sclerosis. Front. Biosci. 9 (2004) 864-872
38. Yong V.W., Wells J., Giuliani F., Casha S., Power C., and Metz L.M. The promise of minocycline in neurology. Lancet. Neurol. 3 (2004) 744-751
39. Zheng T.S., and Flavell R.A. Divinations and surprises: analysis of caspase function in mice. Exp. Cell. Res. 256 (2000) 67-73